Obinutuzumab Improves Response in Active Non-Renal SLE
The ALLEGORY trial establishes that the type II anti-CD20 antibody obinutuzumab, already approved for lupus nephritis, produces substantial clinical responses in adults with active extrarenal systemic lupus erythematosus.
Obinutuzumab improves SLE outcomes in the recent ALLEGORY trial.
This study explores a potential new treatment for systemic lupus erythematosus (SLE) without renal involvement, providing options beyond standard therapy. At week 52, 76.7% of patients on obinutuzumab achieved an SLE Responder Index 4 (SRI-4) response compared to 53.5% on placebo. The findings suggest obinutuzumab may be an effective addition to standard therapy for SLE, improving response rates without significant renal involvement. Obinutuzumab shows promise in enhancing SLE treatment efficacy over a year.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Furie RA, Dall'Era M, Vital EM, Garg JP, Irazoque Palazuelos F, Zuta Santillán AE, Ravelo-Hernández J, Santiago MB, Zazueta Montiel B, Botha S, Leszczyński P, de Souza VA, Sicsik SA, Bellatin L, Naidoo A, Amoura Z, D'Agostino MA, Kumar S, Workeneh B, Rae J, Mao HA, Erblang F, Meier O, Maller JC, Askanase AD, ALLEGORY Trial Investigators
Citation:Furie RA, Dall'Era M, Vital EM, et al. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. The New England journal of medicine. 2026;395(3):243-254. doi:10.1056/NEJMoa2516150